You are here: Industry Insights > teva

News List

Will Mylan’s big Copaxone price break force Teva’s hand? Clients are pushing already fiercepharma
July 17, 2018
Thanks to Mylan’s gigantic price cut on generic Copaxone from earlier this month, Teva’s going to have to take the price on its branded product down. And it would be wise to start now, one analyst says.
Teva to Move US Headquarters to New Jersey americanpharmaceuticalreview
July 11, 2018
New Jersey Governor Phil Murphy announced Teva Pharmaceuticals USA will locate its U.S. headquarters in Parsippany-Troy Hills
Teva Launches Generic Version of Uceris in the United States americanpharmaceuticalreview
July 11, 2018
Teva announced the launch of a generic version of Uceris (budesonide) extended-release tablets, 9 mg, in the U.S.
Teva, lured by $40M tax break, packs its bags for New Jersey HQ move fiercepharma
July 09, 2018
Looks like New Jersey’s $40 million plan to lure Teva’s headquarters from Pennsylvania worked.
Teva axes Phase 3 trial into chronic cluster headache pharmafile
June 22, 2018
With the advent of another week, there’s another trial discontinuation in the industry as Teva announces its decision to terminate further research into its calcitonin gene-related peptide (CGRP)
Teva pulls fremanezumab cluster headaches trial pharmatimes
June 21, 2018
Teva is discontinuing a late-stage trial assessing the efficacy of its experimental anti-CGRP therapy fremanezumab in reducing cluster headaches.
Axovant snatches Teva and Allergan execs to strengthen management pharmafile
June 07, 2018
Axovant has announced reinforcements to its management team with two new additions, snatching up Allergan’s current Chief Medical Officer Dr Gavin Corcoran as its new Executive Vice President of R&D, and Dr Michael Hayden, former Chief Scientific Officer
Teva expects FDA preapproval inspection of troubled Celltrion plant this year fiercepharma
May 07, 2018
Teva said in its first-quarter earnings report that it expects an FDA pre-approval inspection in the coming months of the plant where its partner Celltrion produces the API for Teva's migraine treatment fremanezumab. Wall Street speculation had focused
Cutting costs and Copaxone prices pays off for Teva, sending shares skyward fiercepharma
May 04, 2018
You could say Teva investors are pleasantly surprised. The embattled drugmaker's shares soared 8% in premarket trading Thursday after it unexpectedly raised guidance for the year...
Teva and the Procter & Gamble Company Have Agreed to Terminate the PGT Healthcare Partnership biospace
April 20, 2018
Teva Pharmaceuticals Industries has announced that Teva and the Procter & Gamble Company have agreed to terminate the PGT Healthcare partnership that the two companies established in 2011 to market OTC medicines.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 14 15 Next page